Navigation Links
deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Date:1/31/2008

REYKJAVIK, Iceland, Jan. 31 /PRNewswire-FirstCall/ -- Scientists from deCODE genetics (Nasdaq: DCGN) today report the discovery of two common, single-letter variants in the sequence of the human genome (SNPs) that regulate one of the principle motors of evolution. Versions of the two SNPs, located on chromosome 4p16, have a genome-wide impact on the rate of recombination -- the reshuffling of the genome that occurs in the formation of eggs and sperm. Recombination is largely responsible for generating human diversity, the novel configurations of the genome that enable the species to adapt and evolve in an ever-changing environment. Yet remarkably, the versions of the SNPs that increase recombination in men decrease it in women, and vice versa. This highly unusual characteristic may enable the variants to help to maintain a fundamental tension crucial for evolutionary success: promoting the generation of significant diversity within a portion of the population but keeping the pace of this change within certain bounds, maintaining it relatively constant overall and so supporting the stability of the genome and the cohesiveness of the species.

"This is the latest in a series of landmark papers from deCODE in which we have utilized our unique capabilities in human genetics to elucidate some of the key mechanisms driving human evolution," said Kari Stefansson, CEO of deCODE. "We are also excited that we can now immediately enable individuals to see if they carry such variants, by folding the findings announced today -- and others we expect to publish in the near future -- into our deCODEme(TM) personal genome analysis service."

The deCODE team identified the SNPs through a genome-wide analysis of more than 300,000 SNPs in approximately 20,000 participants in the company's gene discovery programs. The SNPs, referred to as rs3796619 and rs1670533, are within the RNF212 gene, and are estimated to account for approximately 22% of paternal variability in recombination and 6.5% of maternal variability. Little is known about RNF212, though it is a mammalian homolog of a gene called ZHP-3 known to be crucial for the success of recombination in other organisms. The paper, entitled 'Sequence Variants in the RNF212 Gene Associate with Genomewide Recombination Rate,' is published today in the online edition of Science, at http://www.sciencemag.org/sciencexpress.

deCODE has made a number of breakthrough discoveries in the understanding of recombination, fertility and human evolution. In 2002, deCODE published the most detailed recombination map to date of the genome, demonstrating that there are hotspots and coldspots for recombination in all chromosomes, and that these are very different in women and men. This map provided a template for completing the final assembly of the sequence of the human genome. deCODE scientists then showed that recombination rate varies between families and between women; that recombination rate increases with the age of the mother; and that higher recombination rate correlates with fertility, indicating that evolution appears to place a premium on the generation of human diversity. In 2005, deCODE identified a genetic variant that correlates with higher recombination rate, the first genetic variant ever demonstrated to be under positive evolutionary selection in human populations in real time. References for these and all deCODE's major discoveries can be found at http://www.decode.com.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Berglind Olafsdottir Edward Farmer Joy Bessenger

+354 570 2393 +1 212 343 2819 +1 212 481 3891

bro@decode.is edward.farmer@decode.is ir@decode.is


'/>"/>
SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
2. deCODE Launches deCODEme(TM)
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
6. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
7. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
8. Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM)
9. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
10. Nanotechnology innovation may revolutionize gene detection in a single cell
11. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine Company, VetStem ... have treated over 100 of their own patients with the VetStem Cell Therapy. Each ... of care for their patients. , The veterinarians are Dr Ross Rich former ...
Breaking Biology Technology:
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):